CEL-SCI Home Page
preload preload

January 2016

CEL-SCI Shareholder Letter

Press Releases

Corporate Presentations

Press Releases

February 3, 2016
NEW STORY CEL-SCI to Present at 18TH Annual BIO CEO & Investor Conference

February 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial

January 25, 2016
NEW STORY CEL-SCI'S Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

January 14, 2016
NEW STORY CEL-SCI Corporation to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference

January 8, 2016
NEW STORY CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016

January 5, 2016
NEW STORY CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial

December 11, 2015
NEW STORY CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments

December 4, 2015
NEW STORY CEL-SCI's CEO Presentation Available On Company Website

December 1, 2015
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in November for Its Phase 3 Head and Neck Cancer Trial

November 30, 2015
NEW STORY CEL-SCI Corporation To Present At The LD Micro Main Event

November 17, 2015
NEW STORY CEL-SCI Is Granted a New European Patent on Its Phase 3 Investigational Cancer Immunotherapy Multikine

November 4, 2015
NEW STORY CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health

November 2, 2015
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in October for Its Phase 3 Head and Neck Cancer Trial

October 28, 2015
NEW STORY CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $11.5 Million

October 23, 2015
NEW STORY CEL-SCI Prices Public Offering For Up To $12 Million

October 22, 2015
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

October 19, 2015
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders

October 14, 2015
NEW STORY CEL-SCI to Receive Up to $5,000,000 in Litigation Funding to Support Its Arbitration Suit Against Former CRO

October 5, 2015
NEW STORY Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head and Neck Cancer Trial

October 1, 2015
NEW STORY CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial

September 1, 2015
NEW STORY CEL-SCI Reports August Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial

August 7, 2015
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results

August 3, 2015
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial

July 20, 2015
NEW STORY CEL-SCI Expands Its Phase I Study For Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco

July 1, 2015
NEW STORY CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial

June 16, 2015
CEL-SCI to Present at the 2015 Bio International Convention

June 8, 2015
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand

June 1, 2015
CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY